Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

Columbia University

Status and phase: Withdrawn; Phase 3

Conditions: Hyponatremia

Treatments: Drug: Conivaptan; Other: D5

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00684164

AAAC6833

Details and patient eligibility

About

Low sodium levels (hyponatremia) are a frequent occurrence in medically ill patients, and in particular those with neurological injury. Hyponatremia has been associated with worse outcome, problems with memory and concentration and impaired balance. Standard treatment for low sodium (salt) levels is to give the patient a salt containing solution thru a catheter (small flexible tube) in a vein in the arm or leg. One of the major complications of this treatment is excess body fluid which may cause heart problems or accumulation of fluid in the lungs and may require additional medications to remove extra water from the body.

FDA approval has recently been granted for a new drug - Conivaptan - for use in hyponatremic conditions. Conivaptan works by excreting free water from the body and thereby produce concurrent rise in serum sodium concentrations. Conivaptan has not been evaluated specifically in patients with brain injuries. The primary objective of this study is to demonstrate the safety and efficacy of intravenous Conivaptan for the treatment of hyponatremia in patients with brain injury. If effective, Conivaptan may represent a safe treatment option.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute neurological injury
• Euvolemia or hypervolemia (defined clinically by examination, recent I+Os, BUN/creatinine ratio and CVP [if available])
• Serum sodium less than or equal to 132 mEq/L (confirmed as hypoosmolar hyponatremia by a concurrent source: osmolality measurements [<280 mosoms/L] or by a preceding serum Na+ value <135 mEq/L0

Exclusion criteria

• Patients who have uncontrolled hypertension; significant orthostatic hypotension or supine systolic blood pressure less than 85 mm Hg;
• Uncontrolled arrhythmias;
• Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency;
• Estimated creatinine clearance less than 20 ml/min;
• Urinary outflow obstruction unless catheterized;
• Alanine aminotransferase (ALT) >3x ULN
• Aspartate aminotransferase (AST) >3x ULN
• Serum albumin of 1.5 g/dl or less;
• Prothrombin time greater than 22 sec or an international normalized ratio (INR) greater than 2.0 without anticoagulant therapy or 3.0 or more with therapy; a white blood cell count less than 3000/µl;
• HIV infection;
• Active hepatitis.
• Pregnant or nursing
• Participation in a clinical trial of an investigational drug or device within 30 days of screening
• Unable to obtain written consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.

Treatment:

Drug: Conivaptan

2

Placebo Comparator group

Description:

Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.

Treatment:

Other: D5